Replies to post #183061 on Avid Bioservices Inc (CDMO)

[biopharm]

thanks for the complete summary update CJ!eom

[cjgaddy]

Roth Capital Affirms Peregrine at BUY; Remains Encouraged by Progress in FY14...

July 15, 2014 9:56amET
“Roth Capital affirms its Buy rating and $5 price target on Peregrine Pharmaceuticals (Nasdaq: PPHM) following Q2 results issued after...” (prem. membership only)
http://www.streetinsider.com/stock_lookup.php?q=PPHM

= = = =
Roth's Coverage Universe: https://roth2.bluematrix.com/docs/pdf/BLUE.pdf
Roth Capital/Joe Pantginis: init. 7-15-10 Buy/PT=$10, CURR: Buy/$5.00 (7-15-14)
http://www.roth.com

Roth Capital /Joe Pantginis - init. 7-15-10 Buy/PT=$10, CURR: Buy/$5.00 http://www.roth.com
. . .Universe (click link bottom right): http://roth.bluematrix.com/docs/pdf/BLUE.pdf
. . .1-14-13: Roth raises PPHM PT 2.70=>$4.00 ("partnering discussions have new found life") http://tinyurl.com/a9t29lb
. . .1-7-13: Roth ups Neutral to BUY, PT 1.25=>$2.70 (after 2nd-Line NSCLC Review Upd) http://tinyurl.com/bfj7mva
. . .12-11-12: Roth ups PT $.70=>$1.25 after Cotara Ph3 design approval & 12-10-12/10Q-CC.
. . .9-24-12: Roth cuts PT $9=>$.70 after PPHM PR about 2nd-Line NSCLC trial data problems.
. . .9-10-12: Roth ups PT $5=>$9 ("highly encouraged by 2ndLine NSCLC clinical data") http://tinyurl.com/9blrqk7
. . .8-15-12: Roth adds PPHM to focus list as a Top Biotech Pick: http://tinyurl.com/9rx5bps
. . .5-21-12: Roth ups PT $3.30=>$5 ("impressed by the strong 2ndLine NSCLC clinical data") http://tinyurl.com/cnghzyv